The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...

Eli Lilly, which manufactures Mounjaro for diabetes and Zepbound for weight loss, did not respond to USA TODAY's request for comment about the research. This story was updated to add new information.

Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion with China-based ...

play videoThe Ho Central NDC constituency office was vandalised by aggrieved youth supporters Some youth supporters of the governing National Democratic Congress (NDC) in the Ho Central ...

This class of drugs, known as glucagon-like peptide-1 receptor agonists, or GLP-1s, also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight ...

A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...

1:27 Ozempic can lower chances of multiple health conditions but comes with risks, study finds Ozempic, Wegovy, Zepbound and other drugs often used for weight loss may help lower the risk of a ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...